CD79B and diffuse large B-cell lymphoma: Similarly, in a DLBCL preclinical model, BJAB and Granta xenograft tumors responded to anti-CD79b despite having lower surface expression levels of CD79b compared to normal B cells, and the efficacy of anti-CD79b ADCs did not align with surface expression levels of CD79b [31].